Articles tagged "Drug interaction"

2016 American Transplant Congress
NAD⁺Promotes Allograft Survival Independently of CD4⁺CD25⁺Foxp3⁺ Regulatory T Cells.
A. Elkhal, H. Rodriguez Cetina Biefer, H. Uehara, M. Quante, M. Seyda, J. Schuitenmaker, S. Tullius, A. Elkhal.
Surgery, Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a central role in the maintenance of immune tolerance and T cell homeostasis. It is known that Tregs promote…
2016 American Transplant Congress
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
H.-P. Chang,¹ C.-Y. Lee,² C.-C. Si,¹ M.-K. Tsai,² F.-L. Lin Wu.^1,3
¹Graduate Institute of Clinical Pharmacy, National Taiwan University, College of Medicine, Taipei, Taiwan; ²Surgery, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.
Studies on the effect of everolimus on tacrolimus pharmacokinetics (PK) were limited and the results were inconsistent. In contrast, studies showed there was little effect…
2015 American Transplant Congress
Establishment of Diabetes Modeling in Common Marmoset
W. Yuan,¹ S. Fukuda,¹ T. Inoue,² D. Chujo,¹ H. Okochi,¹ E. Sasaki,² M. Shimoda.¹
¹National Center for Global Health and Medicine, Tokyo, Japan; ²Central Institute for Experimental Animals, Kawasaki, Japan.
Background:Diabetic nonhuman primates (NHPs) are considered as the good models for both diabetes mellitus research and islet transplantation research safely into clinical applications. However, there…
2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
O. Rissling, P. Glander, P. Hambach, M. Mai, S. Brakemeier, D. Klonower, F. Halleck, E. Singer, E. Schrezenmeier, M. Duerr, H. Neumayer, K. Budde.
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…
2015 American Transplant Congress
Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
D. Milongo,^1,3 G. Vieu,^2,4,3 S. Blavy,^2,4 A. Del Bello,^1,3 F. Sallusto,⁵ L. Rostaing,^1,3 N. Kamar,^1,3 N. Congy-Jolivet.^2,4,3
¹Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; ²Laboratoire d'Immunologie, CHU de Toulouse, Toulouse, France; ³Université Toulouse III Paul-Sabatier, Toulouse, France; ⁴Laboratoire d'Immunogénétique Moléculaire, EA 3034, Université Toulouse III Paul-Sabatier, Toulouse, France; ⁵Department of Urology, CHU Rangueil, Toulouse, France.
Background: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM)…